Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 3/20 | 0.66 |
| ▸ | TTR | P02766 | 5/20 | 0.64 |
| ▸ | UNG | P13051 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.61 |
| ▸ | TNKS | O95271 | 1/20 | 0.61 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69237 | 1.00 | P4HB (0.66) | P4HBTTRUNGNPSR1HDAC3 | |
| SCHEMBL13860524 | 0.95 | TTR (0.63) | P4HBTTRUNGNPSR1HDAC3 | |
| SCHEMBL13860523 | 0.95 | TTR (0.63) | P4HBTTRUNGNPSR1HDAC3 | |
| SCHEMBL808972 | 0.88 | TTR (0.79) | P4HBTTRUNGFBP1HSD17B10 | |
| SCHEMBL808971 | 0.88 | TTR (0.79) | P4HBTTRUNGFBP1HSD17B10 | |
| SCHEMBL8899992 | 0.88 | TTR (0.79) | P4HBTTRUNGFBP1HSD17B10 | |
| SCHEMBL9075299 | 0.88 | TTR (0.79) | P4HBTTRUNGFBP1HSD17B10 | |
| SCHEMBL69146 | 0.86 | NPSR1 (0.74) | TTRNPSR1HDAC3HDAC1HDAC4 | |
| SCHEMBL271386 | 0.86 | NPSR1 (0.74) | TTRNPSR1HDAC3HDAC1HDAC4 | |
| SCHEMBL7496023 | 0.85 | PKM (0.60) | P4HBTTRNPSR1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | claimed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | claimed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-20200368280-A1 | EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY | Viracta Subsidiary, Inc. | 2020-11-26 | — | — | US | claimed |
| CN-111836636-A | Epigenetic modifiers for cellular immunotherapy | 维拉克塔治疗公司 | 2020-10-27 | — | — | CN | claimed |
| US-20190290646-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | INFINITY SA LLC, AS PURCHASER AGENT | 2019-09-26 | — | — | US | claimed |
| US-20130331313-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | TRUSTEES OF BOSTON UNIVERSITY | 2013-12-12 | — | — | US | claimed |
| US-20110245154-A1 | Methods and Compositions for Treating Viral or Virally-Induced Conditions | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | claimed |
| EP-1746982-A2 | HISTONE DEACETYLASES INHIBITORS AGAINST HYPERLIPIDAEMIAS, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | UNIVERSITA'DEGLI STUDI DI MILANO (IT) | 2007-01-31 | — | — | EP | claimed |
| WO-2005105066-A2 | HISTONE DEACETYLASES INHIBITORS AGAINST HYPERLIPIDAEMIAS, ATHEROSCLEROSIS, CARDIOVASCULAR DISEASES | UNIVERSITA' DEGLI STUDI DI MILANO (IT) | 2005-11-10 | — | — | WO | claimed |
| US-20050075282-A1 | Materials and methods for inhibiting the development of epilepsy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-07 | — | — | US | claimed |
| US-4654412-A | UNSATURATED MONOMERS, FIBERS, FILMS, MOLDINGS | CELANESE CORPORATION (US) | 1987-03-31 | — | — | US | claimed |
| US-20260117185-A1 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | SPINALCYTE, LLC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | VIRACTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000672-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | VIRACTA SUBSIDIARY INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-5052188-A | Desiccant materials for use in gas fired cooling and dehumidification equipment | GAS RESEARCH INSTITUTE (US) | 1991-10-01 | — | — | US | disclosed |
| US-4654412-A | UNSATURATED MONOMERS, FIBERS, FILMS, MOLDINGS | CELANESE CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| US-4120825-A | ZEOLITES | UNION OIL COMPANY OF CALIFORNIA (US) | 1978-10-17 | — | — | US | disclosed |
| US-4066628-A | REACTING ORGANIC ISOCYANATE WITH AN EPOXIDE | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117185-A1 | ENHANCEMENT OF FIBROBLAST PLASTICITY FOR TREATMENT OF DISC DEGENERATION | HDAC3, HDAC4, GSK3B | P4HB 1657/4885TTR 3239/4885UNG 2746/4885 |
| US-20260007676-A1 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES | HDAC9, HDAC4, HDAC5 | P4HB 664/4885TTR 4869/4885UNG 2061/4885 |
| US-20260000672-A1 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY | HDAC7, HDAC8, HDAC9 | P4HB 2555/4885TTR 1885/4885UNG 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.